Using antibodies to target cancer therapeutics

Bibliography

• Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther 2012;91:15-17
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7
   PubMed Web of Science ®Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012;22:3-13
   PubMed Web of Science ®Google Scholar
• Altshuler EP, Serebryanaya DV, Katrukha AG. Generation of recombinant antibodies and means for increasing their affinity. Biochemistry (Mosc) 2010;75:1584-605
   PubMed Web of Science ®Google Scholar
• Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011;317:1261-9
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kuramochi T, Engineering the variable region of therapeutic IgG antibodies. mAbs 2011;3:243-52
   PubMed Web of Science ®Google Scholar
• Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J 2011;6:16-27
   Google Scholar
• Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 2011;25:1-11
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010;12:176-83
   PubMedGoogle Scholar
• Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;13:245-55
   PubMed Web of Science ®Google Scholar
• Magliani W, Conti S, Salati A, Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr Med Chem 2004;11:1793-800
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu Z, Fan D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev Vaccines 2008;7:1547-55
   PubMed Web of Science ®Google Scholar
• Feldwisch J, Tolmachev V, Lendel C, Design of an optimized scaffold for affibody molecules. J Mol Biol 2010;398:232-47
   PubMed Web of Science ®Google Scholar
• Lofblom J, Feldwisch J, Tolmachev V, Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-80
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507
   PubMed Web of Science ®Google Scholar
• Porter RR. A chemical study of rabbit antiovalbumin. Biochem J 1950;46:473-8
   PubMed Web of Science ®Google Scholar
• Nisonoff A, Wissler FC, Lipman LN, Woernley DL. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys 1960;89:230-44
   PubMed Web of Science ®Google Scholar
• Edelman GM, Poulik MD. Studies on structural units of the gamma-globulins. J Exp Med 1961;113:861-84
   PubMed Web of Science ®Google Scholar
• Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008;14:178-83
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009;23:93-109
   PubMed Web of Science ®Google Scholar
• Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010;40:167-81
   PubMed Web of Science ®Google Scholar
• Bird RE, Hardman KD, Jacobson JW, Single-chain antigen-binding proteins. Science 1988;242:423-6
   PubMed Web of Science ®Google Scholar
• Haber E. Engineered antibodies as pharmacological tools. Immunol Rev 1992;130:189-212
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009;562:177-93
   PubMedGoogle Scholar
• Hu S, Shively L, Raubitschek A, Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61
   PubMed Web of Science ®Google Scholar
• Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protocol 2006;1:2048-60
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 2000;1:253-63
   PubMedGoogle Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36
   PubMed Web of Science ®Google Scholar
• Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008;8:600-8
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Sharkey RM, Paganelli G, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs 2008;9:1302-16
   PubMed Web of Science ®Google Scholar
• Pressman D. The zone of localization of antibodies; the specific localization of antibodies to rat kidney. Cancer 1949;2:697-700
   PubMed Web of Science ®Google Scholar
• Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953;6:619-23
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, DeLand F, Kim E, Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-6
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981;41:4354-60
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res 1974;34:1-9
   PubMed Web of Science ®Google Scholar
• Leichner PK, Klein JL, Garrison JB, Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry. Int J Radiat Oncol Biol Phys 1981;7:323-33
   PubMed Web of Science ®Google Scholar
• Order SE, Klein JL, Ettinger D, Use of isotopic immunoglobulin in therapy. Cancer Res 1980;40:3001-7
   PubMed Web of Science ®Google Scholar
• Larson SM, Carrasquillo JA, McGuffin RW, Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 1985;155:487-92
   PubMed Web of Science ®Google Scholar
• Adams DA, DeNardo GL, DeNardo SJ, Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance. Biochem Biophys Res Commun 1985;131:1020-7
   PubMed Web of Science ®Google Scholar
• Badger CC, Krohn KA, Shulman H, Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies. Cancer Res 1986;46:6223-8
   PubMed Web of Science ®Google Scholar
• Rosen ST, Zimmer AM, Goldman-Leikin R, Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 1987;5:562-73
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, DeNardo GL, O'Grady LF, Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 1987;2:49-53
   PubMedGoogle Scholar
• Goldman-Leikin RE, Kaplan EH, Zimmer AM, Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using 131I-T101. Exp Hematol 1988;16:861-4
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Badger CC, Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38
   PubMed Web of Science ®Google Scholar
• DeNardo GL, DeNardo SJ, O'Grady LF, Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990;50:1014s-6s
   PubMed Web of Science ®Google Scholar
• Parker BA, Vassos AB, Halpern SE, Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 1990;50:1022s-8s
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Badger CC, High-dose radioimmunotherapy of B cell lymphomas. Front Radiat Ther Oncol 1990;24:204-13
   PubMedGoogle Scholar
• Goldenberg DM, Horowitz JA, Sharkey RM, Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-64
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Wahl RL, Glenn SD, Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992;52:637-42
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Fig LM, Zasadny KR, Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-711
   PubMed Web of Science ®Google Scholar
• Eary JF, Press OW, Badger CC, Imaging and treatment of B-cell lymphoma. J Nucl Med 1990;31:1257-68
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Appelbaum FR, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zasadny KR, Francis IR, Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65
   PubMed Web of Science ®Google Scholar
• Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005;46(Suppl 1):128S-40S
   PubMed Web of Science ®Google Scholar
• Davis TA, Kaminski MS, Leonard JP, The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792-8
   PubMed Web of Science ®Google Scholar
• Knox SJ, Goris ML, Trisler K, Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Kraeber-Bodere F, Wegener WA, High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:3709-16
   PubMed Web of Science ®Google Scholar
• Wahl RL, Zasadny KR, MacFarlane D, Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S-7S
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009;113:3891-5
   Google Scholar
• Mattes MJ, Sharkey RM, Karacay H, Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008;14:6154-60
   PubMed Web of Science ®Google Scholar
• Gulec SA, Cohen SJ, Pennington KL, Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011;17:4091-100
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Guarino MJ, Pennington KL, Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). J Clin Oncol 2011;29:abstract 240
   Google Scholar
• Ocean AJ, Pennington KL, Guarino MJ, Fractionated radioimmunotherapy (RAIT) with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) and low-dose gemcitabine is active in advanced pancreatic cancer: a phase I trial. Cancer 2012; doi: 10.1002/cncr.27592
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Pykett MJ, Siegel JA, Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987;47:5672-7
   PubMed Web of Science ®Google Scholar
• Siegel JA, Pawlyk DA, Lee RE, Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039s-42s
   PubMed Web of Science ®Google Scholar
• Liersch T, Meller J, Kulle B, Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70
   PubMed Web of Science ®Google Scholar
• Liersch T, Meller J, Bittrich M, Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90
   PubMed Web of Science ®Google Scholar
• Reardan DT, Meares CF, Goodwin DA, Antibodies against metal chelates. Nature 1985;316:265-8
   PubMed Web of Science ®Google Scholar
• Axworthy DB, Reno JM, Hylarides MD, Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000;97:1802-7
   PubMed Web of Science ®Google Scholar
• Karacay H, Brard PY, Sharkey RM, Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879-85
   PubMed Web of Science ®Google Scholar
• Karacay H, Sharkey RM, Gold DV, Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009;50:2008-16
   PubMed Web of Science ®Google Scholar
• Schoffelen R, Sharkey RM, Goldenberg DM, Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 2010;9:1019-27
   PubMed Web of Science ®Google Scholar
• Schoffelen R, van der Graaf WT, Franssen G, Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 2010;51:1780-7
   Google Scholar
• Sharkey RM, Cardillo TM, Rossi EA, Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 2006;24:82-97
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Johnson CR, Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444-53
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Litwin S, Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282-90
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Vallabhajosula S, Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497-507
   Google Scholar
• Chatal JF, Campion L, Kraeber-Bodere F, Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11
   PubMed Web of Science ®Google Scholar
• Schoffelen R, van der Graaf WT, Sharkey RM, Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res 2012;2:5
   Google Scholar
• Sharkey RM, Rossi EA, McBride WJ, Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010;40:190-203
   PubMed Web of Science ®Google Scholar
• Kyriakos RJ, Shih LB, Ong GL, The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835-42
   PubMed Web of Science ®Google Scholar
• Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res 1996;56:3062-8
   PubMed Web of Science ®Google Scholar
• Jain RK. Taming vessels to treat cancer. Sci Am 2008;298:56-63
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Poh MZ, Insin N, Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 2010;99:1342-9
   PubMed Web of Science ®Google Scholar
• Baish JW, Stylianopoulos T, Lanning RM, Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci USA 2011;108:1799-803
   PubMed Web of Science ®Google Scholar
• Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8
   PubMed Web of Science ®Google Scholar
• Saga T, Neumann RD, Heya T, Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 1995;92:8999-9003
   PubMed Web of Science ®Google Scholar
• Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. mAbs 2009;1:247-53
   PubMed Web of Science ®Google Scholar
• Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. mAbs 2012;4:349-61
   PubMedGoogle Scholar
• Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
   PubMed Web of Science ®Google Scholar
• Kellogg BA, Garrett L, Kovtun Y, Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27
   PubMed Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
   PubMed Web of Science ®Google Scholar
• Sun X, Widdison W, Mayo M, Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011;22:728-35
   PubMed Web of Science ®Google Scholar
• Zhao RY, Wilhelm SD, Audette C, Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011;54:3606-23
   PubMed Web of Science ®Google Scholar
• Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther2012; In press
   PubMedGoogle Scholar
• Moon SJ, Govindan SV, Cardillo TM, Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008;51:6916-26
   PubMed Web of Science ®Google Scholar
• Moon SJ, Tat F, Sheerin A, Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy [abstract 2439]. Proc Am Assoc Cancer Res 2010;51:591
   Google Scholar
• Govindan SV, Cardillo TM, Moon SJ, CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61
   PubMed Web of Science ®Google Scholar
• Stein R, Govindan SV, Hayes M, Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Clin Cancer Res 2005;11:2727-34
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther 2011;10:1072-81
   Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61
   PubMed Web of Science ®Google Scholar
• Shih LB, Lu HH, Xuan H, Goldenberg DM. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994;56:538-45
   PubMed Web of Science ®Google Scholar
• Afshar S, Olafsen T, Wu AM, Morrison SL. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT. J Exp Clin Cancer Res 2009;28:147
   PubMedGoogle Scholar
• Bagshawe KD. Targeting: the ADEPT story so far. Curr Drug Targets 2009;10:152-7
   PubMed Web of Science ®Google Scholar
• Schellmann N, Deckert PM, Bachran D, Targeted enzyme prodrug therapies. Mini Rev Med Chem 2010;10:887-904
   PubMed Web of Science ®Google Scholar
• Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 1981;294:171-3
   PubMed Web of Science ®Google Scholar
• Domingo DL, Trowbridge IS. Transferrin receptor as a target for antibody-drug conjugates. Methods Enzymol 1985;112:238-47
   PubMed Web of Science ®Google Scholar
• Friden PM, Walus LR, Musso GF, Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 1991;88:4771-5
   PubMed Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-87
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820:291-317
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012;503:269-92
   PubMed Web of Science ®Google Scholar
• Burton JD, Ely S, Reddy PK, CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11
   PubMed Web of Science ®Google Scholar
• Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15:2855-61
   PubMed Web of Science ®Google Scholar
• Gold DV, Stein R, Burton J, Goldenberg DM. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol 2010;4:1-12
   PubMedGoogle Scholar
• Hansen HJ, Ong GL, Diril H, Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300
   PubMed Web of Science ®Google Scholar
• Griffiths GL, Mattes MJ, Stein R, Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71
   PubMed Web of Science ®Google Scholar
• Chang CH, Sapra P, Vanama SS, Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14
   PubMed Web of Science ®Google Scholar
• Sapra P, Stein R, Pickett J, Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-64
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, Kornblau SM, Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-13
   PubMed Web of Science ®Google Scholar
• Wadleigh M, Richardson PG, Zahrieh D, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-82
   PubMed Web of Science ®Google Scholar
• Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-14
   PubMed Web of Science ®Google Scholar
• Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 2012;21:871-8
   PubMed Web of Science ®Google Scholar
• Advani A, Coiffier B, Czuczman MS, Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403-11
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2006;4:57-62, 76-7
   PubMedGoogle Scholar
• de Vries JF, Zwaan CM, De Bie M, The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012;26:255-64
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Furtado M, Rule S. Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: focus on brentuximab vedotin. Clin Med Insights Oncol 2012;6:31-9
   PubMedGoogle Scholar
• Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 2012;21:205-16
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; doi: 10.1200/JCO.2011.38.0410
   Google Scholar
• Burris HA III, Rugo HS, Vukelja SJ, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Weiss D, Guardino E, Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47
   PubMed Web of Science ®Google Scholar
• Tse KF, Jeffers M, Pollack VA, CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82
   PubMed Web of Science ®Google Scholar
• Naumovski L, Junutula JR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 2010;12:248-57
   PubMed Web of Science ®Google Scholar
• Rose AA, Grosset AA, Dong Z, Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010;16:2147-56
   PubMed Web of Science ®Google Scholar
• Keir CH, Vahdat LT. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 2012;12:259-63
   PubMed Web of Science ®Google Scholar
• Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131-49
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37
   PubMed Web of Science ®Google Scholar
• Alley SC, Zhang X, Okeley NM, The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009;330:932-8
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Mitchell P, Cajulis E, Efficacy of AMG 479, alone and in combination with cisplatin, in ovarian carcinoma xenograft models. Mol Cancer Ther 2009;8:abstract C172
   Google Scholar
• Derycke MS, Pambuccian SE, Gilks CB, Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134:835-45
   PubMed Web of Science ®Google Scholar
• Fabre-Lafay S, Monville F, Garrido-Urbani S, Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73
   PubMed Web of Science ®Google Scholar
• Golfier S, Kahnert A, Heisler I, Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): characterization and anti-tumor activity in mesothelin-positive preclinical tumor models [abstract 1754]. Proc Am Assoc Cancer Res 2011;52:419
   Google Scholar
• Gudas JM, An Z, Morrison RK, ASG-5ME: A novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers [abstract 230]. Genitourinary Cancers Symposium 2010
   Google Scholar
• Hamblett KJ, Kozlosky CJ, Liu H, AMG595, a novel antibody drug conjugate approach for targeting EGFRVIII-espressing glioblastoma. Neurol Oncol 2011;13:abstract ET-36
   Google Scholar
• Oflazoglu E, Stone IJ, Gordon K, Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008;14:6171-80
   PubMed Web of Science ®Google Scholar
• Takano A, Ishikawa N, Nishino R, Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703
   PubMed Web of Science ®Google Scholar
• Thompson JA, Forero-Torres A, Heath EI, The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a phase I study. J Clin Oncol 2011;29:abstract 3071
   Google Scholar
• Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins 2010;2:2645-62
   PubMedGoogle Scholar
• Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011;16:495-503
   Google Scholar
• Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins 2011;3:848-83
   PubMed Web of Science ®Google Scholar
• FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405
   PubMed Web of Science ®Google Scholar
• Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011;23:594-600
   PubMed Web of Science ®Google Scholar
• Pasquetto MV, Vecchia L, Covini D, Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34:611-28
   PubMed Web of Science ®Google Scholar
• Schindler J, Gajavelli S, Ravandi F, A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;154:471-6
   PubMed Web of Science ®Google Scholar
• Weldon JE, Pastan I. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683-700
   PubMed Web of Science ®Google Scholar
• Zielinski R, Lyakhov I, Hassan M, HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 2011;17:5071-81
   PubMed Web of Science ®Google Scholar
• Adkins I, Holubova J, Kosova M, Sadilkova L. Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol 2012
   PubMed Web of Science ®Google Scholar
• Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods Enzymol 2012;502:167-214
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 2011;108:5742-7
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A, Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-28
   PubMed Web of Science ®Google Scholar
• Mussai F, Campana D, Bhojwani D, Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010;150:352-8
   PubMed Web of Science ®Google Scholar
• Wayne AS, Bhojwani D, Silverman LB, A Novel Anti-CD22 Immunotoxin, moxetumomab pasudotox: phase I study in pediatric Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting Abstracts 2011;118:248
   Google Scholar
• Herrera L, Bostrom B, Gore L, A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
   PubMed Web of Science ®Google Scholar
• Herrera L, Farah RA, Pellegrini VA, Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853-8
   PubMed Web of Science ®Google Scholar
• Mohamedali KA, Ran S, Gomez-Manzano C, Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 2011;11:358
   PubMed Web of Science ®Google Scholar
• Lyu MA, Rai D, Ahn KS, The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 2010;12:366-75
   PubMed Web of Science ®Google Scholar
• Cao Y, Marks JD, Huang Q, Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012;11:143-53
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biol Targets Ther 2008;2:601-9
   PubMedGoogle Scholar
• Chang CH, Gupta P, Michel R, Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther 2010;9:2276-86
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Chang CH. The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012;23:309-23
   Google Scholar
• Rossi EA, Chan E, Cardillo TM, Potent ribonuclease-based immunotoxins comprising quadruple ranpirnase (Rap) site-specifically conjugated to B-cell lymphoma-targeting antibodies [abstract 5345]. Proc Am Assoc Cancer Res 2010;51:1295
   Google Scholar
• Cardillo TM, Rossi EA, Arrojo R, A novel immunotoxin comprising quadruple RNase tethered to an internalizing anti-TROP-2 humanized MAb shows potent cytotoxicity against diverse solid tumors in vitro [abstract 5346]. Proc Am Assoc Cancer Res 2010;51:1296
   Google Scholar
• Lode HN, Xiang R, Becker JC, Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998;80:277-92
   PubMed Web of Science ®Google Scholar
• Frey K, Zivanovic A, Schwager K, Neri D. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb) 2011;3:468-78
   Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012;http://dx.doi.org/10.1016/j.drudis.2012.01.007
   PubMed Web of Science ®Google Scholar
• Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 2009;18:991-1000
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Hettmann T, A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85
   PubMed Web of Science ®Google Scholar
• Johannsen M, Spitaleri G, Curigliano G, The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Weide B, de Braud F, A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011;17:7732-42
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012http://dx.doi.org/10.1016/j.abb.2012.03.001
   PubMed Web of Science ®Google Scholar
• Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology or building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13:5586s-91s
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864-71
   Google Scholar
• Rossi EA, Rossi DL, Cardillo TM, Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 2011;118:1877-84
   PubMed Web of Science ®Google Scholar
• Rossi EA, Rossi DL, Stein R, A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010;70:7600-9
   Google Scholar